Research programme: complement protein C3 inhibitor - Incode BioPharmaceuticsAlternative Names: rC3-1
Latest Information Update: 16 Jul 2016
At a glance
- Originator InCode BioPharmaceutics
- Class Enzymes; Recombinant proteins
- Mechanism of Action Complement system protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Paroxysmal nocturnal haemoglobinuria
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Paroxysmal-nocturnal-haemoglobinuria in USA
- 23 Jul 2008 Preclinical trials in Paroxysmal nocturnal haemoglobinuria in USA (unspecified route)